Market Trading Update

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com





Market and media release 10 March 2020
AFT Pharmaceuticals trading update
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today reports it is seeing strong current
demand for its cold and influenza related medicines as customers build stocks
following the Covid-19 outbreak.
Our Australasian over-the-counter and hospital businesses have seen strong demand
for our injectable antibiotics, our suite of analgesics (including our patented
Maxigesic
®
pain relief products) and for our supplements such as Vitamin C
Liposachets
®
.
Meanwhile, international demand for the company’s Maxigesic medicines has also
been strong and we have been working with our international partners to ensure an
uninterrupted supply to our global customer base. This is not without challenges, given
disruption to global trade routes caused by the virus. However, we are confident that
any financial impact on the global business could in part be offset our local sales
gains.
AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “As news of the
Covid-19 outbreak emerged at the start of this year, we moved quickly to significantly
build stocks of our key medicines in Australasia and we have been rewarded for this
foresight.
“By way of example, we sold $1.2m of Vitamin C Liposachets in New Zealand over 3
days alone which represented our prior 12 months sales.
“AFT meanwhile supplies to hospitals across Australasia the injectable antibiotic
Piptaz, which is used to treat pneumonia, a potential complication of the Covid-19
virus. We have seen strong demand for this product and our other injectable
antibiotics as our Australian based customers have increased stocks in preparation for
the possibility of a more serious outbreak.
“While we have seen an uplift of revenue, it has come late in the financial year. We
are therefore retaining our guidance for an operating profit for the 12 months to 31
March 2020 of $18.8 million to $21.8 million, although we now expect a result that is at
the mid to upper end of this range,” Dr Atkinson said.
“AFT is monitoring developments related to the Covid-19 outbreak closely. At present
we are unable to say with any certainty whether demand will be sustained beyond
the end of the current financial year and if so for how long.
“Importantly we have a diverse range of products from injectable antibiotics to
patented analgesic and eyecare products. We will update the market as necessary”

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com

AFT will report its full-year results in late May 2020
For and on behalf of AFT Pharmaceuticals Limited, Dr Hartley Atkinson, Managing
Director.
For more information:
Investors Media
Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over-the-counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded and generic drugs. Our business model is to develop and in-license products
for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to
local licensees and distributors to over 125 countries around the world. For more
information about the company, visit our website www.aftpharm.com.